I think the Andrew left story last week has caused a bit of a squeeze in Cassava Sciences. Casava has an Alzheimer's drug that seems to be the real deal.In comparison to Biogen , and Eli Lillys FDA approved drugs which have marginal efficacy ,at best . Sava has been the victim of a constant short attack, data tampering, and possible sabotage. Sound familiar ? P3 results coming soon, good to see the shorts crapping their pants,